Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Subscribe

Logo for

Science 304 (5675): 1262-1263

Copyright © 2004 by the American Association for the Advancement of Science

IMMUNOLOGY:
Nothing 'gainst Time's Scythe Can Make Defense...

Hidde L. Ploegh

Designing vaccines against viruses or tumor cells that elicit CD8 T cell responses depends on understanding how viral and tumor antigens initiate activation of naãve CD8 T cells. In his Perspective, Ploegh explores several studies published here (Norbury et al., Wolkers et al.) and elsewhere that reveal the pathway from viral or tumor antigens to long-lived peptides that are capable of priming CD8 T cells.

The author is in the Department of Pathology, Harvard Medical School, Boston, MA 02115, USA. E-mail: ploegh{at}hms.harvard.edu

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Targeting HIV-1 Gag into the Defective Ribosomal Product Pathway Enhances MHC Class I Antigen Presentation and CD8+ T Cell Activation.
A. Goldwich, S. S. C. Hahn, S. Schreiber, S. Meier, E. Kampgen, R. Wagner, M. B. Lutz, and U. Schubert (2008)
J. Immunol. 180, 372-382
   Abstract »    Full Text »    PDF »
Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model.
D. Tao, G. Barba-Spaeth, U. Rai, V. Nussenzweig, C. M. Rice, and R. S. Nussenzweig (2005)
J. Exp. Med. 201, 201-209
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882